Efficacy of probiotics, prebiotics, and synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-08-22 DOI:10.1186/s12876-024-03356-y

Youwen Pan, Yafang Yang, Jiale Wu, Haiteng Zhou, Chao Yang

{"title":"Efficacy of probiotics, prebiotics, and synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.","authors":"Youwen Pan, Yafang Yang, Jiale Wu, Haiteng Zhou, Chao Yang","doi":"10.1186/s12876-024-03356-y","DOIUrl":null,"url":null,"abstract":"Background: There is a contradiction in the use of microbiota-therapies, including probiotics, prebiotics, and synbiotics, to improve the condition of patients with nonalcoholic fatty liver disease (NAFLD). The aim of this review was to evaluate the effect of microbiota-therapy on liver injury, inflammation, and lipid levels in individuals with NAFLD.Methods: Using Pubmed, Embase, Cochrane Library, and Web of Science databases were searched for articles on the use of prebiotic, probiotic, or synbiotic for the treatment of patients with NAFLD up to March 2024.Results: Thirty-four studies involving 12,682 individuals were included. Meta-analysis indicated that probiotic, prebiotic, and synbiotic supplementation significantly improved liver injury (hepatic fibrosis, SMD = -0.31; 95% CI: -0.53, -0.09; aspartate aminotransferase, SMD = -0.35; 95% CI: -0.55, -0.15; alanine aminotransferase, SMD = -0.48; 95% CI: -0.71, -0.25; alkaline phosphatase, SMD = -0.81; 95% CI: -1.55, -0.08), lipid profiles (triglycerides, SMD = -0.22; 95% CI: -0.43, -0.02), and inflammatory factors (high-density lipoprotein, SMD = -0.47; 95% CI: -0.88, -0.06; tumour necrosis factor alpha, SMD = -0.86 95% CI: -1.56, -0.56).Conclusion: Overall, supplementation with probiotic, prebiotic, or synbiotic had a positive effect on reducing liver enzymes, lipid profiles, and inflammatory cytokines in patients with NAFLD.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":"24 1","pages":"283"},"PeriodicalIF":4.6000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11342484/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12876-024-03356-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: There is a contradiction in the use of microbiota-therapies, including probiotics, prebiotics, and synbiotics, to improve the condition of patients with nonalcoholic fatty liver disease (NAFLD). The aim of this review was to evaluate the effect of microbiota-therapy on liver injury, inflammation, and lipid levels in individuals with NAFLD.

Methods: Using Pubmed, Embase, Cochrane Library, and Web of Science databases were searched for articles on the use of prebiotic, probiotic, or synbiotic for the treatment of patients with NAFLD up to March 2024.

Results: Thirty-four studies involving 12,682 individuals were included. Meta-analysis indicated that probiotic, prebiotic, and synbiotic supplementation significantly improved liver injury (hepatic fibrosis, SMD = -0.31; 95% CI: -0.53, -0.09; aspartate aminotransferase, SMD = -0.35; 95% CI: -0.55, -0.15; alanine aminotransferase, SMD = -0.48; 95% CI: -0.71, -0.25; alkaline phosphatase, SMD = -0.81; 95% CI: -1.55, -0.08), lipid profiles (triglycerides, SMD = -0.22; 95% CI: -0.43, -0.02), and inflammatory factors (high-density lipoprotein, SMD = -0.47; 95% CI: -0.88, -0.06; tumour necrosis factor alpha, SMD = -0.86 95% CI: -1.56, -0.56).

Conclusion: Overall, supplementation with probiotic, prebiotic, or synbiotic had a positive effect on reducing liver enzymes, lipid profiles, and inflammatory cytokines in patients with NAFLD.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

益生菌、益生元和合生元对非酒精性脂肪肝患者肝酶、血脂和炎症的疗效：随机对照试验的系统回顾和荟萃分析。

背景：在使用微生物群疗法（包括益生菌、益生元和合成益生菌）改善非酒精性脂肪肝（NAFLD）患者的病情方面存在矛盾。本综述旨在评估微生物群疗法对非酒精性脂肪肝患者肝损伤、炎症和血脂水平的影响：使用 Pubmed、Embase、Cochrane Library 和 Web of Science 数据库检索截至 2024 年 3 月有关使用益生菌、益生菌或合成益生菌治疗非酒精性脂肪肝患者的文章：结果：共纳入 34 项研究，涉及 12,682 人。元分析表明，补充益生菌、益生元和合成益生菌可显著改善肝损伤（肝纤维化，SMD = -0.31；95% CI：-0.53，-0.09；天冬氨酸氨基转移酶，SMD = -0.35；95% CI：-0.55，-0.15；丙氨酸氨基转移酶，SMD = -0.48；95% CI：-0.71，-0.25；碱性磷酸酶，SMD = -0.81；95% CI：-1.55，-0.08）、血脂概况（甘油三酯，SMD = -0.22；95% CI：-0.43，-0.02）和炎症因子（高密度脂蛋白，SMD = -0.47；95% CI：-0.88，-0.06；肿瘤坏死因子α，SMD = -0.86 95% CI：-1.56，-0.56）：总之，补充益生菌、益生元或合成益生菌对降低非酒精性脂肪肝患者的肝酶、血脂和炎症细胞因子有积极作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊